Literature DB >> 7967103

A trial to discriminate spontaneous regression from non-regression cases during mass screening for neuroblastoma.

M Nishi1, H Miyake, T Takeda, H Yonemori, J Hanai, Y Kikuchi, N Takasugi.   

Abstract

We tried to discriminate between cases of spontaneous regression and non-regression during mass screening for neuroblastoma, taking advantage of differences in respect to the urinary homoranillic acid/vanillyl mandelic acid (HVA/VMA) ratio and the original tumor site among true positive, false negative and natural occurrence cases. After classifying them into a total of six groups depending on the two factors, ratio: < 1, 1-2 or > or = 2 and tumor site: adrenal or extra-adrenal in origin, we calculated the mathematical probability of a given true positive case being one of spontaneous regression. A tumor of extra-adrenal origin was likely to regress spontaneously, especially one with an HVA/VMA ratio < 1 or > or = 2 (82.2-100%). A tumor of adrenal origin with an HVA/VMA ratio < 1 seemed unlikely to regress spontaneously (0-4%). The present method, employing simple preoperative information, would be useful in future for the selection of true positive cases which should be observed without treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7967103

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  2 in total

1.  Features and outcomes of neonatal neuroblastoma.

Authors:  B Kostyrka; J Li; S V Soundappan; J Cassey; F Alvaro; L Dalla Pozza; Rajendra Kumar
Journal:  Pediatr Surg Int       Date:  2011-06-28       Impact factor: 1.827

2.  A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study.

Authors:  Jed G Nuchtern; Wendy B London; Carol E Barnewolt; Arlene Naranjo; Patrick W McGrady; James D Geiger; Lisa Diller; Mary Lou Schmidt; John M Maris; Susan L Cohn; Robert C Shamberger
Journal:  Ann Surg       Date:  2012-10       Impact factor: 12.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.